Insiders Buy Jushi Holdings Stock Amid Financial Instability

What turned up

Four insiders at Jushi Holdings, a company that operates in the medicinal and adult-use cannabis market, have recently purchased shares in the company. This activity often suggests management's confidence in a company's future prospects.

However, it is critical to note that Jushi has explicitly warned the public not to rely on its previously issued financial statements due to a restatement. This is a significant warning that casts doubt on all historical financial data. The company also has a record of late filings and has changed its auditor, which are additional red flags for investors to consider.

What the numbers say

All historical figures must be viewed with caution, given the company's warning about its past financial reporting.

(in billions of US dollars)	2021	2022	2023	2024	2025
Revenue	$0.21B	$0.28B	$0.27B	$0.26B	$0.26B
Net Income (Loss)	$0.02B	($0.20B)	($0.07B)	($0.05B)	($0.07B)
Operating Cash Flow	($0.01B)	($0.02B)	$0.00B	$0.02B	$0.02B
Shareholders' Equity	$0.18B	$0.05B	($0.01B)	($0.05B)	($0.12B)

Based on these reported figures, revenue has stalled after a period of strong growth. The company has posted significant net losses for the last four reported years, following a profitable 2021. A particularly concerning trend is the decline in shareholders' equity, which has become negative. This means that, based on these reported numbers, the company's liabilities exceed its assets. The number of shares outstanding has remained relatively stable in recent years, so the losses are not being spread over a rapidly expanding share base.

What the company has been doing

Over the past two years, Jushi has seen considerable change. The company has changed its directors or senior officers five times, indicating significant turnover at the leadership level. This period of frequent change can disrupt strategy and operations.

During this time, Jushi also took on new financial obligations on two separate occasions and amended its corporate bylaws. It has frequently filed disclosures for other events it deemed important, suggesting a period of ongoing adjustments and potential restructuring as it navigates its financial challenges.

What changed in the fine print

The company's formal warnings to investors have shifted, suggesting a change in management's focus. New risks highlighted include specific retail licenses in California and New Jersey, indicating these operations are now a key area of attention. Jushi also added a broad disclaimer that "there may be other factors that cause results not to be as anticipated, estimated or intended."

At the same time, it dropped warnings related to a potential dispensary in Ohio and specific locations in Pennsylvania and Virginia. This could mean those initiatives have either been completed or abandoned, allowing management to concentrate its efforts elsewhere.

What this doesn't tell you

This analysis has several important limitations:

• The most significant limitation is the company's own warning not to rely on its past financial statements. This makes it impossible to be certain about its historical performance or financial health.
• Insider buying can be a sign of confidence, but it can also be for other reasons. We don't know the specific motivations of the four insiders who bought shares.
• This analysis is based only on public filings. It does not include any private information or management's day-to-day view of the business.
• The cannabis industry is subject to complex and rapidly changing regulations, which adds a layer of uncertainty not fully captured in financial reports.
• Without stock price data, we cannot see how the market has reacted to the company's numerous announcements and financial reports.